


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Previously Presented) A compound of formula I



in which

R¹ is H, OH, CN, Hal, CONHR, OB, CO₂B, CF₃, NR₂, NRCOR, NRCOOR or NRCONR₂,

R² is NR₂, NRCOR, NRCOOR, NRCONR₂, NO₂, NRSO₂R₂, NRCSR or NRCSNR₂,

R³ is H, OH, CN, Hal, CONHR, OB, CO₂B, CF₃, NO₂, NR₂, NRCOR, NRCOOR or NRCONR₂,

R, independently of one another, are H, B, Het or Ar,

A is a straight-chain or branched, mono- or polysaturated carbon chain having 2, 3, 4, 5, or 6 carbon atoms,

B is a straight-chain or branched alkyl radical having 1, 2, 3, 4, 5 or 6 carbon atoms,

a pharmaceutically usable prodrug, salt thereof, or a mixture thereof in all ratios.

Claim 2 (Previously Presented) A compound of formula I according to Claim 1, wherein R¹ is CN or Hal.

Claim 3 (Previously Presented) A compound of formula I according to Claim 1, wherein R^3 is H.

Claim 4 (Previously Presented) A compound of formula I according to Claim 1 wherein R^2 is NRCOR or NR₂COOR.

Claim 5 (Previously Presented) A compound of formula I according to Claim 1, wherein A is $(CH_2)_m$, where $m = 2, 3, 4, 5$ or 6.

Claim 6 (Previously Presented) A compound of formula I according to Claim 1, wherein R^1 is CN or Hal, and R^3 is H.

Claim 7 (Previously Presented) A compound of formula I according to Claim 1, wherein R^1 is CN, R^3 is H, and A is $(CH_2)_m$, where $m = 4$.

Claim 8 (Previously Presented) A compound of formula I according to Claim 1, wherein R^1 is in position 5 of the indole radical.

Claim 9 (Currently Amended) A compound of formula I which is N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)methylamide,

ethyl (6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,


methyl N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,

N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)-2,2-dimethylpropionamide,


3-{4-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]butyl}-1H-indole-5-carbonitrile,

or a pharmaceutically usable prodrug, or salt thereof.

Claim 10 (Previously Presented) A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula II




in which R² and R³ are as defined in Claim 1, with a compound of formula III




in which R¹ and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.


Claim 11 (Currently Amended) A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula IV



in which R^3 is as defined in Claim 1, and R^4 is an amino-protecting group or H, in a Michael-analogous reaction, with ethyl nitroacetate and diethylammonium chloride, and subsequently reducing the nitro group to give a compound of formula V



and reacting the compound of formula V ~~is reacted~~ with a compound conforming to formula III



in which R^1 and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.

Claim 12 (Canceled)

Claim 13 (Previously Presented) A pharmaceutical composition, comprising an effective amount of a compound of the formula I according to Claim 1, optionally in addition to one or more inert excipients, adjuvants and/or diluents, and a pharmaceutically acceptable

carrier.

Claim 14 (Canceled)

Claim 15 (Previously Presented) A process for the preparation of a composition according to Claim 13, comprising combining a compound of formula I with one or more inert excipients and/or diluents by non-chemical methods.

Claim 16 (Canceled)

Claim 17 (Currently Amended) A method for treating depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ~~brain or spinal cord trauma~~, obsessive-compulsive disorder, ~~sleeping disorders, or~~ tardive dyskinesia, ~~learning disorders, age-related memory disorders, eating disorders, or sexual dysfunctions~~, comprising administering to a host in need thereof a compound according to Claim 1.

Claim 18 (Canceled)

Claim 19. (Previously Presented) A method for treating depression, strokes, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, or Alzheimer's disease, comprising administering to a host in need thereof a compound according to Claim 1.

Claim 20. (New) A compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

Claim 21. (New) A compound according to Claim 9 or a pharmaceutically acceptable salt thereof.